La trimétazidine (Vastarel) est-elle un produit dopant ? Proposition pour une suppression de la liste des produits interdits de l’Agence mondiale anti-dopage
Author:
- Pascal KintzPKPascal Kintz
- 1 December 2020
- journal article
- editorial
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 32 (4) , 239-241
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Trimetazidine and parkinsonism: A prospective studyParkinsonism & Related Disorders, 2019
- Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failureIndian Heart Journal, 2017
- Trimetazidine improves exercise tolerance in patients with ischemic heart diseaseHerz, 2015
- The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trialsInternational Journal of Cardiology, 2014
- The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administrationDrug Testing and Analysis, 2014
- Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 casesFundamental & Clinical Pharmacology, 2011
- Cardiac Lesions Induced by Testosterone: Protective Effects of Dexrazoxane and TrimetazidineCardiovascular Toxicology, 2009
- Trimetazidine Induces Parkinsonism, Gait Disorders and TremorTherapies, 2005
- Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2003
- The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2003